Results 261 to 270 of about 122,919 (308)
Some of the next articles are maybe not open access.
Viral Immunology, 2003
Debates are still being waged over what is the best strategy for developing a potent AIDS vaccine. All the obvious approaches to making AIDS vaccines have been tried in the past two decades without much success. It is clear that new thinking and a revision of prevailing dogmas needs to be in place if we really want a vaccine.
Aldar S, Bourinbaiar +2 more
openaire +2 more sources
Debates are still being waged over what is the best strategy for developing a potent AIDS vaccine. All the obvious approaches to making AIDS vaccines have been tried in the past two decades without much success. It is clear that new thinking and a revision of prevailing dogmas needs to be in place if we really want a vaccine.
Aldar S, Bourinbaiar +2 more
openaire +2 more sources
Current Pharmaceutical Design, 2006
Therapeutic HIV vaccines represent promising strategy as an adjunct or alternative to current antiretroviral treatment options for HIV. Unlike prophylactic AIDS vaccines designed to prevent HIV infection, therapeutic vaccines are given to already infected individuals to help fight the disease by modulating their immune response.
A S, Bourinbaiar +6 more
openaire +2 more sources
Therapeutic HIV vaccines represent promising strategy as an adjunct or alternative to current antiretroviral treatment options for HIV. Unlike prophylactic AIDS vaccines designed to prevent HIV infection, therapeutic vaccines are given to already infected individuals to help fight the disease by modulating their immune response.
A S, Bourinbaiar +6 more
openaire +2 more sources
Science, 2008
A quarter century of scientific discovery has been applied to developing an AIDS vaccine, yet this goal remains elusive. Specific characteristics of the virus, including the extreme genetic variability in circulating viral isolates worldwide, biological properties of HIV that impede immune attack, and a high mutation rate that allows for rapid escape ...
Bruce D, Walker, Dennis R, Burton
openaire +2 more sources
A quarter century of scientific discovery has been applied to developing an AIDS vaccine, yet this goal remains elusive. Specific characteristics of the virus, including the extreme genetic variability in circulating viral isolates worldwide, biological properties of HIV that impede immune attack, and a high mutation rate that allows for rapid escape ...
Bruce D, Walker, Dennis R, Burton
openaire +2 more sources
JAMA, 1994
Worldwide, the human immunodeficiency virus type 1 (HIV-1) has already infected 10 million to 15 million people. With an estimated 5000 to 10 000 new infections occurring each day, 30 million to 40 million people will be infected by the year 2000. 1 In developing countries, where more than 80% of new infections are occurring, the virus is predominantly
openaire +1 more source
Worldwide, the human immunodeficiency virus type 1 (HIV-1) has already infected 10 million to 15 million people. With an estimated 5000 to 10 000 new infections occurring each day, 30 million to 40 million people will be infected by the year 2000. 1 In developing countries, where more than 80% of new infections are occurring, the virus is predominantly
openaire +1 more source
Vaccine, 1999
In spite of extensive prevention programs, the HIV epidemics is still spreading worldwide, in particularly in developing countries where clade C viruses predominate. WHO estimates that there are 16, 000 new cases of HIV infection daily and that 100 M individuals will be infected by the end of the next decade.
openaire +2 more sources
In spite of extensive prevention programs, the HIV epidemics is still spreading worldwide, in particularly in developing countries where clade C viruses predominate. WHO estimates that there are 16, 000 new cases of HIV infection daily and that 100 M individuals will be infected by the end of the next decade.
openaire +2 more sources
Clinical Pharmacology & Therapeutics, 2007
Development of an HIV/AIDS vaccine has been slow because classical approaches to vaccine development have not yielded a vaccine. Encouragingly, new approaches using recombinant viral vectors, DNA vaccines, and combinations of different vectors in heterologous prime/boost regimens are yielding vaccines capable of controlling virulent immunodeficiency ...
openaire +2 more sources
Development of an HIV/AIDS vaccine has been slow because classical approaches to vaccine development have not yielded a vaccine. Encouragingly, new approaches using recombinant viral vectors, DNA vaccines, and combinations of different vectors in heterologous prime/boost regimens are yielding vaccines capable of controlling virulent immunodeficiency ...
openaire +2 more sources
Science, 1998
In recent months, the U.S. National Institutes of Health (NIH) human immunodeficency virus (HIV) vaccine research program has been criticized by a few activists and public health figures who serve on, or have provided testimony to, the President's Advisory Committee on HIV/AIDS (PACHA) (M. Balter,
Moises Agosto +56 more
openaire +1 more source
In recent months, the U.S. National Institutes of Health (NIH) human immunodeficency virus (HIV) vaccine research program has been criticized by a few activists and public health figures who serve on, or have provided testimony to, the President's Advisory Committee on HIV/AIDS (PACHA) (M. Balter,
Moises Agosto +56 more
openaire +1 more source